BTMDHealthcare · Medical Care FacilitiesThe 5 Wall Street analysts covering biote Corp. hold a median 12-month price target of $2.5 — +54.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores biote Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (11): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BTMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +54.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | B. Riley Securities | Maintains | Neutral | $2.00 → $1.50 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $2.50 → $2.00 |
| 16 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 16 Apr 2026 | Truist Securities | Maintains | Buy | $5.00 → $4.00 |
| 12 Mar 2026 | B. Riley Securities | Maintains | Neutral | — |
| 12 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2025 | B. Riley Securities | Downgrade | Neutral | — |
| 13 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 16 Dec 2024 | Craig-Hallum | Initiates | Buy | — |
| 13 Mar 2024 | Roth MKM | Reiterates | Buy | — |
| 20 Feb 2024 | B. Riley Securities | Initiates | Buy | — |
| 1 Feb 2024 | Jefferies | Initiates | Buy | — |
| 18 Jan 2024 | Roth MKM | Maintains | Buy | — |
| 18 Jan 2024 | Truist Securities | Maintains | Buy | — |
| 15 Aug 2023 | TD Cowen | Maintains | Outperform | — |
| 14 Aug 2023 | Roth MKM | Reiterates | Buy | — |
| 30 Mar 2023 | Roth MKM | Maintains | Buy | — |
| 27 Sept 2022 | Truist Securities | Initiates | Buy | — |
| 24 June 2022 | Cowen & Co. | Initiates | Outperform | — |
| 23 June 2022 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BTMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 90% of US stocks
Cheaper than 95% of US stocks
Cheaper than 50% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 82% of US stocks
Higher than 55% of US stocks
Higher than 55% of US stocks
Higher than 20% of US stocks
Higher than 96% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own biote Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
biote Corp. (BTMD) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item provides access to the company's earnings-call discussion for the second quarter of 2026.
Why it matters — A BTMD watcher would care because the transcript offers direct insight into the company's Q2 2026 results and management commentary.
biote Corp. (BTMD) reported break-even earnings per share for Q2, below the Zacks Consensus Estimate of $0.03 and down from earnings of $0.10 per share in the same quarter a year ago.
Why it matters — BTMD watchers would note that the company fell short of analyst expectations and declined year over year, signaling weaker quarterly profitability.
biote reported lower second-quarter revenue and a net loss, driven by a voluntary recall of certain hormone pellets supplied by Asteria Health that disrupted procedure volumes. Management said supply conditions have since normalized and should support sequential improvement in the second half of 2026.
Why it matters — A BTMD watcher would care because the recall-related supply disruption depressed recent results, while the normalization of supply and expected second-half improvement signal how the company's current operations are expected to recover.
Biote (NASDAQ: BTMD) announced its financial results for the second quarter ended June 30, 2026. Management said the company made meaningful progress on strategic initiatives and fundamental improvements over the past year, positioning it for sustainable procedure revenue growth.
Why it matters — BTMD watchers would care because the quarterly results and management's commentary provide a current update on the company's strategic progress and its outlook for future procedure revenue growth.
The 5 Wall Street analysts covering biote Corp. have a median 12-month price target of $2.5, with estimates ranging from $1.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering biote Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks biote Corp. 71 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, biote Corp. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +54.8% from the last close, and Ticker Nerd's factor model ranks biote Corp. 71 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering biote Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BTMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $4 over the next 12 months.
biote Corp. returned -46.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Biote Corp. is a healthcare company specializing in hormone optimization and preventive medicine.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "biote Corp. (BTMD) Q2 2026 Earnings Call Transcript". biote Corp. (BTMD) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item provides access to the company's earnings-call discussion for the second quarter of 2026.
Biote Corp. is a healthcare company specializing in hormone optimization and preventive medicine. It operates a comprehensive practice-building platform known as the Biote Method, which equips certified practitioners with education, training, certification, practice management software, inventory management tools, and digital marketing support to deliver bioidentical hormone replacement pellet therapy. This therapy addresses hormonal imbalances in men and women, promoting therapeutic wellness and healthy aging. Biote Corp. also offers Biote-branded dietary supplements and sterile pellet insertion kits essential for hormone optimization treatments. The company supports a network of physicians and nurse practitioners, enabling them to implement personalized hormone therapy programs effectively. Through its end-to-end solutions, Biote Corp. plays a key role in the growing hormone optimization sector within preventive healthcare. Founded in 2012 and headquartered in Irving, Texas, it focuses on empowering providers to optimize patient hormone levels using precise, bioidentical approaches.
CEO Mr. Robert C. Peterson · 223 employees · United States · https://www.biote.com